Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 13/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | TOP1 | P11387 | 1/20 | 0.42 |
| ▸ | USP1 | O94782 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665418 | 0.90 | CHRM1 (0.60) | CHRM1JAK2JAK3TOP1USP1 | |
| SCHEMBL11895782 | 0.87 | CHRM1 (0.55) | CHRM1P2RX3TOP1 | |
| SCHEMBL15868735 | 0.84 | P2RX3 (0.50) | CHRM1P2RX3KDM4EALDH1A1 | |
| SCHEMBL1665806 | 0.82 | P2RX3 (0.51) | CHRM1JAK2JAK3P2RX3TOP1 | |
| SCHEMBL16628324 | 0.81 | CHRM1 (0.68) | CHRM1TOP1 | |
| SCHEMBL16161714 | 0.80 | P2RX3 (0.43) | CHRM1P2RX3KDM4EALDH1A1 | |
| SCHEMBL21043089 | 0.79 | CHRM1 (0.75) | CHRM1 | |
| SCHEMBL1666185 | 0.79 | CHRM1 (0.44) | CHRM1JAK2JAK3P2RX3TOP1 | |
| SCHEMBL1932467 | 0.79 | CHRM1 (0.52) | CHRM1JAK2JAK3P2RX3TOP1 | |
| SCHEMBL15863323 | 0.77 | LMNA (0.43) | P2RX3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170290834-A1 | Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-10-12 | — | — | US | claimed |
| EP-2945945-B1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-08-31 | — | — | EP | claimed |
| US-20160039818-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-02-11 | — | — | US | claimed |
| US-9199987-B2 | Substituted naphthyridines for the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AU) | 2015-12-01 | — | — | US | claimed |
| US-20170290834-A1 | Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-10-12 | — | — | US | disclosed |
| US-9505758-B2 | Substituted 1,5-naphthyridines as endonuclease inhibitors | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-11-29 | — | — | US | disclosed |
| EP-2945945-B1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-08-31 | — | — | EP | disclosed |
| US-20160039818-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-02-11 | — | — | US | disclosed |
| US-9199987-B2 | Substituted naphthyridines for the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AU) | 2015-12-01 | — | — | US | disclosed |
| EP-2945945-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | Savira Pharmaceuticals GmbH (AT) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014108408-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-17 | — | — | WO | disclosed |
| US-20140194432-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-10 | — | — | US | disclosed |
| US-8426438-B2 | Heterocyclic-fused pyrazolo[4,3-c]pyridin-3-one M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2483275-A1 | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Schering Corporation (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120178760-A1 | Heterocyclic-Fused Pyrazolo[4,3-c] Pyridin-3-One M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| WO-2011041143-A1 | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290834-A1 | Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease | XDH, CYP27A1, ALAD | CHRM1 2260/4885JAK2 3544/4885JAK3 1741/4885 |
| US-20120178760-A1 | Heterocyclic-Fused Pyrazolo[4,3-c] Pyridin-3-One M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM4, CHRM2 | CHRM1 1/4885JAK2 3555/4885JAK3 2110/4885 |
| US-20140194432-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | XDH, CYP27A1, ALAD | CHRM1 2260/4885JAK2 3544/4885JAK3 1741/4885 |
| US-20160039818-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | XDH, CYP27A1, ALAD | CHRM1 2260/4885JAK2 3544/4885JAK3 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.